Details for Patent: 10,669,544
✉ Email this page to a colleague
Which drugs does patent 10,669,544 protect, and when does it expire?
Patent 10,669,544 protects LEQVIO and is included in one NDA.
This patent has fifty-seven patent family members in nine countries.
Summary for Patent: 10,669,544
| Title: | Therapeutic compositions |
| Abstract: | This application relates to therapeutic siRNA agents and methods of making and using the agents. |
| Inventor(s): | Manoharan; Muthiah (Cambridge, MA), Rajeev; Kallanthottathil G. (Cambridge, MA), Bumcrot; David (Cambridge, MA) |
| Assignee: | Alnylam Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 16/352,964 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,669,544
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,669,544
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 479752 | ⤷ Sign Up | |||
| Australia | 2004220556 | ⤷ Sign Up | |||
| Australia | 2004227414 | ⤷ Sign Up | |||
| Australia | 2004229519 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
